Literature DB >> 11444495

Analysis of vasodilator responses to novel nitric oxide donors in the hindquarters vascular bed of the cat.

T J Bivalacqua1, H C Champion, B J De Witt, J E Saavedra, J A Hrabie, L K Keefer, P J Kadowitz.   

Abstract

Controlled release of nitric oxide (NO*) may be useful in the treatment of a variety of vascular disorders. NO* donors of the diazeniumdiolate family with different rates of spontaneous NO* release have been synthesized. In the current study responses to seven diazeniumdiolate NO* donors (DEA/NO*, DETA/NO*, OXI/NO*, PIPERAZI/NO*, PROLI/NO*, SPER/NO*, and SULFI/NO*) were investigated in the hindquarters vascular bed of the cat. Intravenous injections of all NO* donors caused dose-dependent decreases in systemic arterial pressure and the rank order of potency was SNP > DEA/NO* > PIPERAZI/NO* > SPER/NO* > PROLI/NO* > OXI/NO*. Injections of all NO* donors into the hindlimb perfusion circuit caused dose-related decreases in hindquarters perfusion pressure that were similar to the order of potency in decreasing systemic arterial pressure. The rank order of the time required for the response to return to 50% of the maximal decrease in pressure (T(1/2)) and total duration of action of the NO* donors was SPER/NO* > PIPERAZI/NO* > DEA/NO* > OXI/NO* > DETA/NO* > PROLI/NO* > SULFI/NO*. After treatment with the NO* synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (100 mg/kg, i.v.), hindlimb vasodilator responses to the NO* donors were not significantly different, but vasodilator responses to acetylcholine were significantly reduced. After treatment with zaprinast (2 mg/kg, i.v.), a type V cyclic 3',5'-guanosine monophosphate-specific phosphodiesterase inhibitor, the duration of vasodilator responses to the NO* donors, as measured by T(1/2), was increased significantly, whereas the duration of the response to the beta2-adrenergic receptor agonist albuterol was unchanged. These data suggest that diazeniumdiolate NO* donors are endothelium-independent, directly stimulate soluble guanylate cyclase, and decrease vascular resistance by increasing cyclic 3',5'-guanosine monophosphate levels in the hindquarters vascular bed of the cat.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444495     DOI: 10.1097/00005344-200107000-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Anna E Maciag; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2008-10-29       Impact factor: 6.005

2.  Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species.

Authors:  Daniel A Langer; Amitava Das; David Semela; Ningling Kang-Decker; Helen Hendrickson; Steven F Bronk; Zvonimir S Katusic; Gregory J Gores; Vijay H Shah
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

3.  Mechanisms underlying maternal venous adaptation in pregnancy.

Authors:  Cresta Wedel Jones; Maurizio Mandala; Carolyn Barron; Ira Bernstein; George Osol
Journal:  Reprod Sci       Date:  2009-03-24       Impact factor: 3.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.